Shionogi has raised its consolidated earnings outlook and dividend forecast for the fiscal year ending March 2027. The company raised its forecasts for net income and annual dividends, factoring in strong sales of HIV drugs and infectious disease products.
Shionogi announced that it had raised its consolidated earnings outlook and dividend forecast for the fiscal year ending March 2027. The company expects earnings to improve, factoring in strong performance in its HIV drug business and increased product sales in the infectious disease field.
The new net income forecast was raised from ¥210.0 billion to ¥212.5 billion, up 1.6% year on year. The annual dividend forecast was raised from ¥76 to ¥86, compared with ¥71 in the previous fiscal year.
In the second half, royalty income and equity-method investment gains are expected to increase as ViiV Healthcare, which operates the HIV business, continues to perform strongly. Sales of insomnia treatment drugs in Japan are also expected to grow. Meanwhile, costs related to the acquisition of US biotech company Intrabio are expected to increase, but the company plans to pursue cost control.